Tepotinib vs Vebreltinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline

Tepotinib · Tepmetko

Marketed by Merck KGaA and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT02864992 · Phase 2 · active, not recruiting

The study was open-label and had no randomized comparator arm, so the reported tumor responses cannot be distinguished from outcomes that might have occurred with other treatment or without tepotinib. Although response was assessed by an independent review committee and results were reported for 337 participants, the primary endpoint was descriptive in this single-arm design.

Next expected readout: December 2027 · NCT06083857 (registry estimate)

Reported efficacy

Objective response rate (ORR) by independent review committee (IRC): ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months (not_applicable)

Result source: NCT02864992

Vebreltinib

Marketed by Avistone Biotechnology under a licence from Apollomics Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT04258033 · Phase 2 · completed

This is an open-label, single-arm study with no randomization and no comparator group. The response rate in cohort 1 was high and its confidence interval cleared a preset benchmark, but without a control group the size of the drug's effect cannot be judged directly.

Next expected readout: December 2026 · NCT06343064 (registry estimate)

Reported efficacy

Objective response rate (2 years): Primary endpoint objective response rate 75% (95% CI, 61.1 to 86) per blinded independent review committee (met)

Result source: NCT04258033

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTepotinibVebreltinib
PFS, median4.9 vs 4.4vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
1 other result
  • 10.2 vs 4.3 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955
—Trial running · NCT06970782
OS, median17.3 vs 19.5vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955—Trial running · NCT06970782
ORR45.2% vs 33.3%vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
2 other results
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955
—Trial running · NCT06970782
Duration of response, median—Trial running · NCT06908993—Trial running · NCT06970782

PFS, median

Tepotinib
4.9 vs 4.4vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
1 other result
  • 10.2 vs 4.3 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955
Vebreltinib
—Trial running · NCT06970782

OS, median

Tepotinib
17.3 vs 19.5vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
Vebreltinib
—Trial running · NCT06970782

ORR

Tepotinib
45.2% vs 33.3%vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
2 other results
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955
Vebreltinib
—Trial running · NCT06970782

Duration of response, median

Tepotinib
—Trial running · NCT06908993
Vebreltinib
—Trial running · NCT06970782
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Vebreltinib
Primary endpoint objective response rate 75% (95% CI, 61.1 to 86) per blinded independent review committee NCT04258033 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Tepotinib: 3 of 4 rows · Vebreltinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTepotinib
Dropout rate
0%500 mg + 250 mga
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
0%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
0%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—500 mg + 250 mga
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
—500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
58.3%500 mg + 250 mga
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
41.9%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
66.7%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
500 mg + 250 mga
diarrhoea 83.3%
dyspnoea exertional 41.7%
fatigue 41.7%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
500 mg + 250 mg
diarrhoea 58.1%
oedema peripheral 38.7%
amylase increased 35.5%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
300 mg + 250 mg
amylase increased 66.7%
diarrhoea 66.7%
blood alkaline phosphatase increased 50%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tepotinib

PFS 4.86 vs 4.37 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mg
time to event · months
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
10.15 vs 4.34 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
ORR 33.3% (n=12)500 mg + 250 mg
responder rate · % of participants
No placebo or comparator arm
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
33.3% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 58.3% (n=12)500 mg + 250 mg
responder rate · % of participants
No placebo or comparator arm
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
50% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival 17.25 vs 19.48 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mg
time to event · months
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
ORR 45.2% (n=31) vs 33.3% (n=24) Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg
responder rate · % of participants
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 83.9% (n=31) vs 70.8% (n=24) Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg
responder rate · % of participants
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS -16.29 vs -2.78 Pemetrexed and Cisplatin/Carboplatin score500 mg + 250 mg
absolute change · score
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Time to Symptomatic Progression 5.75 vs 7.95 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mg
time to event · months
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tepotinib's landscape · Vebreltinib's landscape